{‘She lacks zero qualifications’: the US scientific establishment girds for Tracy Beth Høeg’s appointment at the FDA.

While America continues making sweeping revisions to its vaccination guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning COVID-19 shots during the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her recent tenure at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders were set to announce major changes to the childhood vaccination calendar in December, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of alignment with much of the global community with insufficient data for benefit. This reveal has been delayed until the new year.

Instead of Vinay Prasad, Høeg is listed to address the audience at the event. She was newly appointed acting director of the FDA’s CDER, the fifth person to head the office this year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no obvious track record in medication creation, oversight or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the CDER, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “understand regulatory frameworks and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that previous people who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the generic program authorizes thousands of generic medications. There is also a biosimilars program, OTC medication office and more, and all of those must be looked after,” Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a substantial leadership aspect to the position, which manages over 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” Woodcock said.

Response and Contentious Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among agency officials on vaccines, a representative stated that the “concerns are based on inaccurate assumptions”.

“This background is consistent with the responsibilities of her position,” the spokesperson said, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial expedited review system, a contentious one-day therapy clearance system that reportedly troubled her predecessors. “By what process are these medications being selected for this voucher program? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Public Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, critics said. She published a analysis using non-validated crowd-sourced reports to estimate the incidence of heart inflammation following Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Part of her “wish list” for the incoming administration encompassed altering regulations for new vaccines and discontinuing “non-essential” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has according to sources proposed preventing young men from getting Covid vaccines.

“She’s an complete ideologue who begins with her beliefs and tailors the evidence to fit the data in a extremely disingenuous, dishonest way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|